 | • レポートコード：MRC2-11QY02430 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は甲状腺未分化癌治療薬のグローバル市場について調査・分析したレポートです。種類別（CLM-94、クロリブリン、エファタゾン、GLONC-2、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別甲状腺未分化癌治療薬の競争状況、市場シェア ・世界の甲状腺未分化癌治療薬市場：種類別市場規模 2015年-2020年（CLM-94、クロリブリン、エファタゾン、GLONC-2、その他） ・世界の甲状腺未分化癌治療薬市場：種類別市場規模予測 2021年-2026年（CLM-94、クロリブリン、エファタゾン、GLONC-2、その他） ・世界の甲状腺未分化癌治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の甲状腺未分化癌治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の甲状腺未分化癌治療薬市場分析：米国、カナダ ・ヨーロッパの甲状腺未分化癌治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの甲状腺未分化癌治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の甲状腺未分化癌治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの甲状腺未分化癌治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Daiichi Sankyo Company, Limited、Genelux Corporation、Immune Pharmaceuticals Inc.、Millennium Pharmaceuticals Inc、Novartis AG、Pfizer Inc.、Plexxikon Inc.、Trophogen, Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Anaplastic Thyroid Cancer Drug Market
The global Anaplastic Thyroid Cancer Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Anaplastic Thyroid Cancer Drug Scope and Market Size
Anaplastic Thyroid Cancer Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anaplastic Thyroid Cancer Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Anaplastic Thyroid Cancer Drug market is segmented into
CLM-94
Crolibulin
Efatutazone
GLONC-2
Others
Segment by Application, the Anaplastic Thyroid Cancer Drug market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Anaplastic Thyroid Cancer Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Anaplastic Thyroid Cancer Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Anaplastic Thyroid Cancer Drug Market Share Analysis
Anaplastic Thyroid Cancer Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Anaplastic Thyroid Cancer Drug business, the date to enter into the Anaplastic Thyroid Cancer Drug market, Anaplastic Thyroid Cancer Drug product introduction, recent developments, etc.
The major vendors covered:
Daiichi Sankyo Company, Limited
Genelux Corporation
Immune Pharmaceuticals Inc.
Millennium Pharmaceuticals Inc
Novartis AG
Pfizer Inc.
Plexxikon Inc.
Trophogen, Inc.
1 Study Coverage
1.1 Anaplastic Thyroid Cancer Drug Product Introduction
1.2 Market Segments
1.3 Key Anaplastic Thyroid Cancer Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Anaplastic Thyroid Cancer Drug Market Size Growth Rate by Type
1.4.2 CLM-94
1.4.3 Crolibulin
1.4.4 Efatutazone
1.4.5 GLONC-2
1.4.6 Others
1.5 Market by Application
1.5.1 Global Anaplastic Thyroid Cancer Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Anaplastic Thyroid Cancer Drug Market Size, Estimates and Forecasts
2.1.1 Global Anaplastic Thyroid Cancer Drug Revenue 2015-2026
2.1.2 Global Anaplastic Thyroid Cancer Drug Sales 2015-2026
2.2 Global Anaplastic Thyroid Cancer Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Anaplastic Thyroid Cancer Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Anaplastic Thyroid Cancer Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Anaplastic Thyroid Cancer Drug Competitor Landscape by Players
3.1 Anaplastic Thyroid Cancer Drug Sales by Manufacturers
3.1.1 Anaplastic Thyroid Cancer Drug Sales by Manufacturers (2015-2020)
3.1.2 Anaplastic Thyroid Cancer Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Anaplastic Thyroid Cancer Drug Revenue by Manufacturers
3.2.1 Anaplastic Thyroid Cancer Drug Revenue by Manufacturers (2015-2020)
3.2.2 Anaplastic Thyroid Cancer Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Anaplastic Thyroid Cancer Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Anaplastic Thyroid Cancer Drug Revenue in 2019
3.2.5 Global Anaplastic Thyroid Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Anaplastic Thyroid Cancer Drug Price by Manufacturers
3.4 Anaplastic Thyroid Cancer Drug Manufacturing Base Distribution, Product Types
3.4.1 Anaplastic Thyroid Cancer Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Anaplastic Thyroid Cancer Drug Product Type
3.4.3 Date of International Manufacturers Enter into Anaplastic Thyroid Cancer Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Anaplastic Thyroid Cancer Drug Market Size by Type (2015-2020)
4.1.1 Global Anaplastic Thyroid Cancer Drug Sales by Type (2015-2020)
4.1.2 Global Anaplastic Thyroid Cancer Drug Revenue by Type (2015-2020)
4.1.3 Anaplastic Thyroid Cancer Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Anaplastic Thyroid Cancer Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Anaplastic Thyroid Cancer Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Anaplastic Thyroid Cancer Drug Revenue Forecast by Type (2021-2026)
4.2.3 Anaplastic Thyroid Cancer Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Anaplastic Thyroid Cancer Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Anaplastic Thyroid Cancer Drug Market Size by Application (2015-2020)
5.1.1 Global Anaplastic Thyroid Cancer Drug Sales by Application (2015-2020)
5.1.2 Global Anaplastic Thyroid Cancer Drug Revenue by Application (2015-2020)
5.1.3 Anaplastic Thyroid Cancer Drug Price by Application (2015-2020)
5.2 Anaplastic Thyroid Cancer Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Anaplastic Thyroid Cancer Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Anaplastic Thyroid Cancer Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Anaplastic Thyroid Cancer Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Anaplastic Thyroid Cancer Drug by Country
6.1.1 North America Anaplastic Thyroid Cancer Drug Sales by Country
6.1.2 North America Anaplastic Thyroid Cancer Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Anaplastic Thyroid Cancer Drug Market Facts & Figures by Type
6.3 North America Anaplastic Thyroid Cancer Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Anaplastic Thyroid Cancer Drug by Country
7.1.1 Europe Anaplastic Thyroid Cancer Drug Sales by Country
7.1.2 Europe Anaplastic Thyroid Cancer Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Anaplastic Thyroid Cancer Drug Market Facts & Figures by Type
7.3 Europe Anaplastic Thyroid Cancer Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Anaplastic Thyroid Cancer Drug by Region
8.1.1 Asia Pacific Anaplastic Thyroid Cancer Drug Sales by Region
8.1.2 Asia Pacific Anaplastic Thyroid Cancer Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Anaplastic Thyroid Cancer Drug Market Facts & Figures by Type
8.3 Asia Pacific Anaplastic Thyroid Cancer Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Anaplastic Thyroid Cancer Drug by Country
9.1.1 Latin America Anaplastic Thyroid Cancer Drug Sales by Country
9.1.2 Latin America Anaplastic Thyroid Cancer Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Anaplastic Thyroid Cancer Drug Market Facts & Figures by Type
9.3 Central & South America Anaplastic Thyroid Cancer Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Anaplastic Thyroid Cancer Drug by Country
10.1.1 Middle East and Africa Anaplastic Thyroid Cancer Drug Sales by Country
10.1.2 Middle East and Africa Anaplastic Thyroid Cancer Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Anaplastic Thyroid Cancer Drug Market Facts & Figures by Type
10.3 Middle East and Africa Anaplastic Thyroid Cancer Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Daiichi Sankyo Company, Limited
11.1.1 Daiichi Sankyo Company, Limited Corporation Information
11.1.2 Daiichi Sankyo Company, Limited Description and Business Overview
11.1.3 Daiichi Sankyo Company, Limited Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Daiichi Sankyo Company, Limited Anaplastic Thyroid Cancer Drug Products Offered
11.1.5 Daiichi Sankyo Company, Limited Related Developments
11.2 Genelux Corporation
11.2.1 Genelux Corporation Corporation Information
11.2.2 Genelux Corporation Description and Business Overview
11.2.3 Genelux Corporation Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Genelux Corporation Anaplastic Thyroid Cancer Drug Products Offered
11.2.5 Genelux Corporation Related Developments
11.3 Immune Pharmaceuticals Inc.
11.3.1 Immune Pharmaceuticals Inc. Corporation Information
11.3.2 Immune Pharmaceuticals Inc. Description and Business Overview
11.3.3 Immune Pharmaceuticals Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Immune Pharmaceuticals Inc. Anaplastic Thyroid Cancer Drug Products Offered
11.3.5 Immune Pharmaceuticals Inc. Related Developments
11.4 Millennium Pharmaceuticals Inc
11.4.1 Millennium Pharmaceuticals Inc Corporation Information
11.4.2 Millennium Pharmaceuticals Inc Description and Business Overview
11.4.3 Millennium Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Millennium Pharmaceuticals Inc Anaplastic Thyroid Cancer Drug Products Offered
11.4.5 Millennium Pharmaceuticals Inc Related Developments
11.5 Novartis AG
11.5.1 Novartis AG Corporation Information
11.5.2 Novartis AG Description and Business Overview
11.5.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Novartis AG Anaplastic Thyroid Cancer Drug Products Offered
11.5.5 Novartis AG Related Developments
11.6 Pfizer Inc.
11.6.1 Pfizer Inc. Corporation Information
11.6.2 Pfizer Inc. Description and Business Overview
11.6.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Pfizer Inc. Anaplastic Thyroid Cancer Drug Products Offered
11.6.5 Pfizer Inc. Related Developments
11.7 Plexxikon Inc.
11.7.1 Plexxikon Inc. Corporation Information
11.7.2 Plexxikon Inc. Description and Business Overview
11.7.3 Plexxikon Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Plexxikon Inc. Anaplastic Thyroid Cancer Drug Products Offered
11.7.5 Plexxikon Inc. Related Developments
11.8 Trophogen, Inc.
11.8.1 Trophogen, Inc. Corporation Information
11.8.2 Trophogen, Inc. Description and Business Overview
11.8.3 Trophogen, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Trophogen, Inc. Anaplastic Thyroid Cancer Drug Products Offered
11.8.5 Trophogen, Inc. Related Developments
11.1 Daiichi Sankyo Company, Limited
11.1.1 Daiichi Sankyo Company, Limited Corporation Information
11.1.2 Daiichi Sankyo Company, Limited Description and Business Overview
11.1.3 Daiichi Sankyo Company, Limited Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Daiichi Sankyo Company, Limited Anaplastic Thyroid Cancer Drug Products Offered
11.1.5 Daiichi Sankyo Company, Limited Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Anaplastic Thyroid Cancer Drug Market Estimates and Projections by Region
12.1.1 Global Anaplastic Thyroid Cancer Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Anaplastic Thyroid Cancer Drug Revenue Forecast by Regions 2021-2026
12.2 North America Anaplastic Thyroid Cancer Drug Market Size Forecast (2021-2026)
12.2.1 North America: Anaplastic Thyroid Cancer Drug Sales Forecast (2021-2026)
12.2.2 North America: Anaplastic Thyroid Cancer Drug Revenue Forecast (2021-2026)
12.2.3 North America: Anaplastic Thyroid Cancer Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Anaplastic Thyroid Cancer Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Anaplastic Thyroid Cancer Drug Sales Forecast (2021-2026)
12.3.2 Europe: Anaplastic Thyroid Cancer Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Anaplastic Thyroid Cancer Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Anaplastic Thyroid Cancer Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Anaplastic Thyroid Cancer Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Anaplastic Thyroid Cancer Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Anaplastic Thyroid Cancer Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Anaplastic Thyroid Cancer Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Anaplastic Thyroid Cancer Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Anaplastic Thyroid Cancer Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Anaplastic Thyroid Cancer Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Anaplastic Thyroid Cancer Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Anaplastic Thyroid Cancer Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Anaplastic Thyroid Cancer Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Anaplastic Thyroid Cancer Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Anaplastic Thyroid Cancer Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Anaplastic Thyroid Cancer Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Anaplastic Thyroid Cancer Drug Market Segments
Table 2. Ranking of Global Top Anaplastic Thyroid Cancer Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Anaplastic Thyroid Cancer Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of CLM-94
Table 5. Major Manufacturers of Crolibulin
Table 6. Major Manufacturers of Efatutazone
Table 7. Major Manufacturers of GLONC-2
Table 8. Major Manufacturers of Others
Table 9. Global Anaplastic Thyroid Cancer Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Anaplastic Thyroid Cancer Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Anaplastic Thyroid Cancer Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Anaplastic Thyroid Cancer Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Anaplastic Thyroid Cancer Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Anaplastic Thyroid Cancer Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Anaplastic Thyroid Cancer Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Anaplastic Thyroid Cancer Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anaplastic Thyroid Cancer Drug as of 2019)
Table 18. Anaplastic Thyroid Cancer Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Anaplastic Thyroid Cancer Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Anaplastic Thyroid Cancer Drug Price (2015-2020) (USD/Pcs)
Table 21. Anaplastic Thyroid Cancer Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Anaplastic Thyroid Cancer Drug Product Type
Table 23. Date of International Manufacturers Enter into Anaplastic Thyroid Cancer Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Anaplastic Thyroid Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Anaplastic Thyroid Cancer Drug Sales Share by Type (2015-2020)
Table 27. Global Anaplastic Thyroid Cancer Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Anaplastic Thyroid Cancer Drug Revenue Share by Type (2015-2020)
Table 29. Anaplastic Thyroid Cancer Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Anaplastic Thyroid Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Anaplastic Thyroid Cancer Drug Sales Share by Application (2015-2020)
Table 32. North America Anaplastic Thyroid Cancer Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Anaplastic Thyroid Cancer Drug Sales Market Share by Country (2015-2020)
Table 34. North America Anaplastic Thyroid Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Anaplastic Thyroid Cancer Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Anaplastic Thyroid Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2015-2020)
Table 38. North America Anaplastic Thyroid Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Anaplastic Thyroid Cancer Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Anaplastic Thyroid Cancer Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Anaplastic Thyroid Cancer Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Anaplastic Thyroid Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Anaplastic Thyroid Cancer Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Anaplastic Thyroid Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Anaplastic Thyroid Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Anaplastic Thyroid Cancer Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Anaplastic Thyroid Cancer Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Anaplastic Thyroid Cancer Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Anaplastic Thyroid Cancer Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Anaplastic Thyroid Cancer Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Anaplastic Thyroid Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Anaplastic Thyroid Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Anaplastic Thyroid Cancer Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Anaplastic Thyroid Cancer Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Anaplastic Thyroid Cancer Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Anaplastic Thyroid Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Anaplastic Thyroid Cancer Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Anaplastic Thyroid Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Anaplastic Thyroid Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Anaplastic Thyroid Cancer Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Anaplastic Thyroid Cancer Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Anaplastic Thyroid Cancer Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Anaplastic Thyroid Cancer Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Anaplastic Thyroid Cancer Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Anaplastic Thyroid Cancer Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Anaplastic Thyroid Cancer Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Anaplastic Thyroid Cancer Drug Sales Market Share by Application (2015-2020)
Table 72. Daiichi Sankyo Company, Limited Corporation Information
Table 73. Daiichi Sankyo Company, Limited Description and Major Businesses
Table 74. Daiichi Sankyo Company, Limited Anaplastic Thyroid Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Daiichi Sankyo Company, Limited Product
Table 76. Daiichi Sankyo Company, Limited Recent Development
Table 77. Genelux Corporation Corporation Information
Table 78. Genelux Corporation Description and Major Businesses
Table 79. Genelux Corporation Anaplastic Thyroid Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Genelux Corporation Product
Table 81. Genelux Corporation Recent Development
Table 82. Immune Pharmaceuticals Inc. Corporation Information
Table 83. Immune Pharmaceuticals Inc. Description and Major Businesses
Table 84. Immune Pharmaceuticals Inc. Anaplastic Thyroid Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Immune Pharmaceuticals Inc. Product
Table 86. Immune Pharmaceuticals Inc. Recent Development
Table 87. Millennium Pharmaceuticals Inc Corporation Information
Table 88. Millennium Pharmaceuticals Inc Description and Major Businesses
Table 89. Millennium Pharmaceuticals Inc Anaplastic Thyroid Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Millennium Pharmaceuticals Inc Product
Table 91. Millennium Pharmaceuticals Inc Recent Development
Table 92. Novartis AG Corporation Information
Table 93. Novartis AG Description and Major Businesses
Table 94. Novartis AG Anaplastic Thyroid Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Novartis AG Product
Table 96. Novartis AG Recent Development
Table 97. Pfizer Inc. Corporation Information
Table 98. Pfizer Inc. Description and Major Businesses
Table 99. Pfizer Inc. Anaplastic Thyroid Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Pfizer Inc. Product
Table 101. Pfizer Inc. Recent Development
Table 102. Plexxikon Inc. Corporation Information
Table 103. Plexxikon Inc. Description and Major Businesses
Table 104. Plexxikon Inc. Anaplastic Thyroid Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. Plexxikon Inc. Product
Table 106. Plexxikon Inc. Recent Development
Table 107. Trophogen, Inc. Corporation Information
Table 108. Trophogen, Inc. Description and Major Businesses
Table 109. Trophogen, Inc. Anaplastic Thyroid Cancer Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. Trophogen, Inc. Product
Table 111. Trophogen, Inc. Recent Development
Table 112. Global Anaplastic Thyroid Cancer Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 113. Global Anaplastic Thyroid Cancer Drug Sales Market Share Forecast by Regions (2021-2026)
Table 114. Global Anaplastic Thyroid Cancer Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 115. Global Anaplastic Thyroid Cancer Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 116. North America: Anaplastic Thyroid Cancer Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 117. North America: Anaplastic Thyroid Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 118. Europe: Anaplastic Thyroid Cancer Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 119. Europe: Anaplastic Thyroid Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 120. Asia Pacific: Anaplastic Thyroid Cancer Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 121. Asia Pacific: Anaplastic Thyroid Cancer Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 122. Latin America: Anaplastic Thyroid Cancer Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 123. Latin America: Anaplastic Thyroid Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 124. Middle East and Africa: Anaplastic Thyroid Cancer Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 125. Middle East and Africa: Anaplastic Thyroid Cancer Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 126. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 127. Key Challenges
Table 128. Market Risks
Table 129. Main Points Interviewed from Key Anaplastic Thyroid Cancer Drug Players
Table 130. Anaplastic Thyroid Cancer Drug Customers List
Table 131. Anaplastic Thyroid Cancer Drug Distributors List
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Anaplastic Thyroid Cancer Drug Product Picture
Figure 2. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Type in 2020 & 2026
Figure 3. CLM-94 Product Picture
Figure 4. Crolibulin Product Picture
Figure 5. Efatutazone Product Picture
Figure 6. GLONC-2 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Anaplastic Thyroid Cancer Drug Report Years Considered
Figure 13. Global Anaplastic Thyroid Cancer Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global Anaplastic Thyroid Cancer Drug Sales 2015-2026 (K Pcs)
Figure 15. Global Anaplastic Thyroid Cancer Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Region (2015-2020)
Figure 17. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Region in 2019
Figure 18. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Region in 2019
Figure 20. Global Anaplastic Thyroid Cancer Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Anaplastic Thyroid Cancer Drug Revenue in 2019
Figure 22. Anaplastic Thyroid Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2015-2020)
Figure 24. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Type in 2019
Figure 25. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Type in 2019
Figure 27. Global Anaplastic Thyroid Cancer Drug Market Share by Price Range (2015-2020)
Figure 28. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Application (2015-2020)
Figure 29. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Application in 2019
Figure 30. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Application in 2019
Figure 32. North America Anaplastic Thyroid Cancer Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Anaplastic Thyroid Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Anaplastic Thyroid Cancer Drug Sales Market Share by Country in 2019
Figure 35. North America Anaplastic Thyroid Cancer Drug Revenue Market Share by Country in 2019
Figure 36. U.S. Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Anaplastic Thyroid Cancer Drug Market Share by Type in 2019
Figure 41. North America Anaplastic Thyroid Cancer Drug Market Share by Application in 2019
Figure 42. Europe Anaplastic Thyroid Cancer Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Anaplastic Thyroid Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Anaplastic Thyroid Cancer Drug Sales Market Share by Country in 2019
Figure 45. Europe Anaplastic Thyroid Cancer Drug Revenue Market Share by Country in 2019
Figure 46. Germany Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Anaplastic Thyroid Cancer Drug Market Share by Type in 2019
Figure 57. Europe Anaplastic Thyroid Cancer Drug Market Share by Application in 2019
Figure 58. Asia Pacific Anaplastic Thyroid Cancer Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Anaplastic Thyroid Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Anaplastic Thyroid Cancer Drug Sales Market Share by Region in 2019
Figure 61. Asia Pacific Anaplastic Thyroid Cancer Drug Revenue Market Share by Region in 2019
Figure 62. China Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Anaplastic Thyroid Cancer Drug Market Share by Type in 2019
Figure 85. Asia Pacific Anaplastic Thyroid Cancer Drug Market Share by Application in 2019
Figure 86. Latin America Anaplastic Thyroid Cancer Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Anaplastic Thyroid Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Anaplastic Thyroid Cancer Drug Sales Market Share by Country in 2019
Figure 89. Latin America Anaplastic Thyroid Cancer Drug Revenue Market Share by Country in 2019
Figure 90. Mexico Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Anaplastic Thyroid Cancer Drug Market Share by Type in 2019
Figure 97. Latin America Anaplastic Thyroid Cancer Drug Market Share by Application in 2019
Figure 98. Middle East and Africa Anaplastic Thyroid Cancer Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Anaplastic Thyroid Cancer Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Anaplastic Thyroid Cancer Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Anaplastic Thyroid Cancer Drug Revenue Market Share by Country in 2019
Figure 102. Turkey Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Anaplastic Thyroid Cancer Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Anaplastic Thyroid Cancer Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Anaplastic Thyroid Cancer Drug Market Share by Type in 2019
Figure 109. Middle East and Africa Anaplastic Thyroid Cancer Drug Market Share by Application in 2019
Figure 110. North America Anaplastic Thyroid Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Anaplastic Thyroid Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Anaplastic Thyroid Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Anaplastic Thyroid Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Anaplastic Thyroid Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Anaplastic Thyroid Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Anaplastic Thyroid Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Anaplastic Thyroid Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Anaplastic Thyroid Cancer Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Anaplastic Thyroid Cancer Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
甲状腺がん治療の世界市場（～2026年） Market Analysis and Insights: Global Thyroid Cancer Treatment Market The global Thyroid Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Thyroid Cancer Treatment Scope and Market Size Thyroid Cancer Tre…- 退形成性乏突起星細胞腫薬の世界市場（～2026年） Market Analysis and Insights: Global Anaplastic Oligoastrocytoma Drug Market The global Anaplastic Oligoastrocytoma Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Anaplastic Oligoastrocytoma Drug Scope and Market…
- 退形成性星細胞腫薬の世界市場（～2026年） Market Analysis and Insights: Global Anaplastic Astrocytoma Drug Market The global Anaplastic Astrocytoma Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Anaplastic Astrocytoma Drug Scope and Market Size Anaplasti…
- 退形成性乏突起星細胞腫の世界市場（～2026年） Oligoastrocytomas is a part of a group of brain tumor called “gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is divided …
- 甲状腺障害治療の世界市場（～2026年） Hormones released by thyroid gland play a crucial role in stimulating metabolism, growth, and calories processing. Globally, thyroid gland disorders such as hypothyroidism, hyperthyroidism, and thyroid nodules affect around 5% to 10% of the population. Hyperthyroidism and hypothyroidism affect major…